Analysts think SPRO stock price could increase by 462%
Jun 14, 2024, 6:27 AM
-1.84%
What does SPRO do
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focuses on developing treatments for bacterial infections, including multi-drug resistant infections, and rare diseases. Its main products include tebipenem HBr, an oral antibiotic for urinary tract infections, SPR720 for non-tuberculous mycobacterial infections, and SPR206, an IV treatment for MDR Gram-negative bacterial infections.
4 analysts think SPRO stock price will increase by 462.50%. The current median analyst target is $7.65 compared to a current stock price of $1.36. The lowest analysts target is $7.07 and the highest analyst target is $8.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
